SynthesisFrontiers in immunology2026
Serum neurofilament light chain and multiple sclerosis prognosis: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum neurofilament light chain (sNfL) has emerged as a promising biomarker of neuroaxonal injury in multiple sclerosis (MS), but its prognostic value for clinical and radiological outcomes requires comprehensive synthesis of available evidence. Methods: In this meta-analysis, we systematically searched PubMed, Embase, Ovid, and Cochrane databases from January 2015 to January 2026 for studies evaluating the association between baseline sNfL levels (high vs low) and MS progression outcomes. Primary outcomes were new clinical relapse (NCR) and ≥1 gadolinium-enhancing (Gd+) lesion. Secondary outcomes included relapse within 1 year (R1Y), new T2 lesions (NTL), and confirmed disease worsening. Random-effects models were used to pool risk ratios (RRs) with 95% CIs. Results: Among 3,281 identified records, 13 studies (n=12,513 patients) were included. Elevated sNfL was significantly associated with increased risk of NCR (6 studies; RR 1.42, 95% CI 1.30-1.54; P<0.01) and ≥1 Gd+ lesion (5 studies; RR 1.47, 1.39-1.56; P<0.01), with low heterogeneity (I²≤34.9%). Consistent associations were also observed for NTL (4 studies; RR 2.11, 95% CI 1.59-2.64; P<0.01) and disease worsening (5 studies; RR 2.10, 95% CI 1.57-2.63; P<0.01), although the latter showed moderate heterogeneity (I²=60.7%). An association was observed for R1Y (2 studies; RR 1.94, 95% CI 1.11-2.76; P<0.01), although the evidence for this outcome remains limited. No substantial publication bias was detected for the main outcomes, and leave-one-out sensitivity analyses confirmed the robustness of the results. Conclusion: Elevated sNfL concentrations are consistently associated with increased risks of clinical relapse, radiological activity, and disability progression in MS, supporting its utility as a prognostic biomarker for stratifying disease course and informing clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.